Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Puma Biotechnology (PBYI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,266,199
  • Shares Outstanding, K 38,498
  • Annual Sales, $ 250,990 K
  • Annual Income, $ -113,580 K
  • 60-Month Beta 0.70
  • Price/Sales 5.04
  • Price/Cash Flow N/A
  • Price/Book 36.53

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.69
  • Number of Estimates 1
  • High Estimate -0.69
  • Low Estimate -0.69
  • Prior Year -0.65
  • Growth Rate Est. (year over year) -6.15%

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.11 +2.43%
on 04/18/19
43.26 -23.97%
on 03/19/19
-9.48 (-22.37%)
since 03/18/19
3-Month
23.65 +39.07%
on 01/22/19
43.90 -25.08%
on 03/18/19
+7.67 (+30.41%)
since 01/18/19
52-Week
17.60 +86.87%
on 11/02/18
68.90 -52.26%
on 04/27/18
-32.06 (-49.36%)
since 04/18/18

Most Recent Stories

More News
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on April 3, 2019 the Compensation Committee of Puma's Board of Directors approved the grant of inducement...

PBYI : 32.89 (+0.09%)
Puma Biotech Adds Two Cohorts to Nerlynx Label Expansion Study

Puma Biotech (PBYI) increases cohorts in the phase II SUMMIT basket study on Nerlynx for cancer patients suffering tumors with activating EGFR or HER2 mutations.

PDLI : 3.58 (+3.47%)
PBYI : 32.89 (+0.09%)
RHHBY : 32.6900 (-0.09%)
KMDA : 6.17 (-1.44%)
Puma Biotechnology Expands Cohorts in Phase II SUMMIT Trial of Neratinib in Cancer Patients with Tumors with Activating EGFR or HER2 Mutations

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, has expanded two additional cohorts from the Phase II SUMMIT clinical trial investigating its lead drug candidate neratinib...

PBYI : 32.89 (+0.09%)
Puma Biotech Out-Licenses Nerlynx Rights in Europe, Stock Down

Puma Biotech (PBYI) out-licenses development and marketing rights to its breast cancer drug Nerlynx to Pierre Fabre in Europe and across some African countries. Shares fall.

PDLI : 3.58 (+3.47%)
PBYI : 32.89 (+0.09%)
RHHBY : 32.6900 (-0.09%)
KMDA : 6.17 (-1.44%)
The Zacks Analyst Blog Highlights: Celgene, Puma, Exelixis, Enanta and Sage

The Zacks Analyst Blog Highlights: Celgene, Puma, Exelixis, Enanta and Sage

CELG : 93.76 (-0.57%)
ENTA : 85.80 (+0.78%)
PBYI : 32.89 (+0.09%)
EXEL : 20.90 (-2.15%)
SAGE : 164.73 (+2.02%)
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX(R) (neratinib) in Europe

Puma Biotechnology, Inc. (Nasdaq: PBYI) and Pierre Fabre have entered into an exclusive license agreement under which Pierre Fabre will develop and commercialize NERLYNX(R) (neratinib) within...

PBYI : 32.89 (+0.09%)
Why Is Puma Biotech (PBYI) Up 39.5% Since Last Earnings Report?

Puma Biotech (PBYI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

PBYI : 32.89 (+0.09%)
Biotech Stocks Outperform During Inversions: 5 Must Watch

An inverted yield curve signals a recession but it is often bullish for biotech stocks.

CELG : 93.76 (-0.57%)
ENTA : 85.80 (+0.78%)
PBYI : 32.89 (+0.09%)
EXEL : 20.90 (-2.15%)
SAGE : 164.73 (+2.02%)
PFE : 39.38 (-1.25%)
BMY : 45.52 (-0.61%)
Puma Biotechnology Announces Publication of Abstracts on Neratinib for AACR Annual Meeting 2019

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced publication of abstracts on neratinib for the American Association for Cancer Research (AACR) Annual Meeting...

PBYI : 32.89 (+0.09%)
Puma Biotech's (PBYI) Nerlynx Gets Approval in Australia

Puma Biotech (PBYI) gains an approval in Australia for Nerlynx as an extended adjuvant treatment in adult patients with early stage HER2-positive breast cancer.

TRVN : 1.50 (unch)
CELG : 93.76 (-0.57%)
PBYI : 32.89 (+0.09%)
RHHBY : 32.6900 (-0.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade PBYI with:

Business Summary

Puma Biotechnology, Inc. is a biopharmaceutical company focused on the acquisition, in-licensing, development and commercialization of novel therapeutics for the treatment of cancer. Its products under development include PB272 (oral neratinib) for the treatment of patients with human epidermal growth...

See More

Key Turning Points

2nd Resistance Point 33.84
1st Resistance Point 33.36
Last Price 32.89
1st Support Level 32.26
2nd Support Level 31.64

See More

52-Week High 68.90
Fibonacci 61.8% 49.30
Fibonacci 50% 43.25
Fibonacci 38.2% 37.20
Last Price 32.89
52-Week Low 17.60

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar